Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618870 | 1.00 | HTR2A (0.31) | HTR2AHRH1TDP1 | |
| SCHEMBL2751203 | 1.00 | HTR2A (0.31) | HTR2AHRH1TDP1 | |
| Hydrochloric Acid SCHEMBL1765230 | 0.97 | TDP1 (0.33) | HTR2AHRH1TDP1 | |
| Hydrochloric Acid SCHEMBL1765228 | 0.97 | TDP1 (0.33) | HTR2AHRH1TDP1 | |
| SCHEMBL14498940 | 0.76 | TSHR (0.31) | TDP1 | |
| SCHEMBL11470552 | 0.76 | HTR2A (0.33) | HTR2AHRH1TDP1 | |
| SCHEMBL6498330 | 0.73 | DPP4 (0.33) | — | |
| SCHEMBL9945520 | 0.71 | — | — | |
| SCHEMBL172806 | 0.70 | HTR2A (0.32) | HTR2AHRH1TDP1 | |
| SCHEMBL14279093 | 0.70 | HTR2A (0.32) | HTR2AHRH1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064192-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8609706-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY DISCOVERY, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8178690-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110213145-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7928244-B2 | Isoxazolidine small molecules; cancer, hyperproliferation disorders; blocking antiapoptotic function | INFINITY DISCOVERY, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213145-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | HTR2A 2812/4885HRH1 3619/4885TDP1 2499/4885 |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | HTR2A 2812/4885HRH1 3619/4885TDP1 2499/4885 |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | HTR2A 2812/4885HRH1 3619/4885TDP1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.